Skip to main content
. 2016 Jun 16;1(9):e86462. doi: 10.1172/jci.insight.86462

Figure 2. Th17 adoptive transfer recipient EAE mice were refractory to treatment with FTY720.

Figure 2

Mean clinical scores of C57BL/6J (WT) recipients of donor encephalitogenic cells from MOG35-55-immunized C57BL/6J (WT) or S1PR1(S5A) mice. Splenocytes were cultured and treated with rIL-23 (10 ng/ml) to generate Th17-polarized cells (A) or with rIL-12 (10 ng/ml) to generate Th1-polarized cells (B) for 72 hours in the presence of MOG35-55 peptide before transfer. Recipient mice were treated with either vehicle (1% cyclodextrin in PBS) or FTY720 (0.5 mg/kg) by daily i.p. injections from day 0 to 34 after transfer. Arrows indicate time of initiation of therapy. This experiment was performed 3 times with n = 10–15 mice/arm. (C) Histopathology of a representative section from formalin-fixed, paraffin-embedded CNS tissue from mice recipient of Th17-polarized cells from WT or S1PR1(S5A) mice following treatment with vehicle or FTY720. Scale bar: 50 μm. Donors: females, 8–12 weeks; recipients: females, 5–6 weeks. *P < 0.05, Mann-Whitney U test.